Cytosorbents Corp 8-K

What Happened

• On June 24, 2026, CytoSorbents Corporation presented at the 2026 Life Sciences Forum and announced it has scheduled two pre-submission meetings with the U.S. Food and Drug Administration in August 2026 to discuss the company’s ticagrelor and direct oral anticoagulant (DOAC) programs.
• The company furnished the presentation as Exhibit 99.1 in a Form 8-K filed June 25, 2026, and noted the disclosure was made under Regulation FD (stating no admission as to materiality).

Key Details

• Date of presentation: June 24, 2026; Form 8-K filed June 25, 2026.
• Two pre-submission meetings with the FDA are scheduled for August 2026.
• Programs discussed: ticagrelor and DOAC (direct oral anticoagulant) programs.
• Presentation furnished as Exhibit 99.1 to the Form 8-K.

Why It Matters

• Pre-submission meetings with the FDA are a routine regulatory step where a company and regulators discuss data, study design, and submission expectations before a formal regulatory filing.
• For investors, these meetings can provide clarity on regulatory requirements and potential next steps for the programs; outcomes or follow-up communications could affect program timelines or clinical/regulatory strategy.
• The filing is informational under Regulation FD; the company did not characterize the information as material beyond the disclosure.